For semaglutide, the prescribing information says steady-state exposure is reached after four to five weeks of once-weekly dosing
KLLA: Jens Juul Holst, professor vid Institutionen fr biomedicinsk vetenskap vid Kpenhamns universitet och forskare vid Novo Nordisk Foundation Centre for Basic Metabolism Research
CL: Formal analysis, Investigation, Resources, Writing original draft, Data curation, Methodology, Software
Expanding Applications: Clinical trials are actively investigating the use of GLP-1 RAs for a wider range of conditions, including addiction, kidney disease, and neurodegenerative disorders, based on their broad physiological effects
However, it is essential to note that when additional pharmacological intervention is required to control diabetes mellitus, the choice between SGLT-2 inhibitors and GLP-1 RAs should be based on the patients individual needs and the specific medications already being used
Patients discontinuing GLP-1 medications should monitor for signs of gallbladder problems (severe abdominal pain, especially after meals), pancreatitis (persistent severe abdominal pain, sometimes with vomiting), or significant hyperglycemia
